SAT Kartar Shopping Ltd (SATKARTAR) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management lowered FY27 revenue growth guidance to 30-35% to strategically accelerate its higher-margin hospital business rollout.
- The hospital vertical is projected to lift consolidated PAT margin to 17-18% in FY28, a significant increase from the previous 14-15% target.
- The US business will commence revenue generation from November 2026, with all operational setups like warehousing and influencer partnerships already in place.
Performance Overview
- Evolved from an Ayurveda products company to an integrated Ayurveda healthcare business, incorporating products, hospitals, and wellness.
- Achieved an operational breakeven milestone for the first 30-bed Ayurveda hospital in Delhi in September 2026.
- Demonstrated improving operating profitability with EBITDA growth outpacing revenue growth in H1 FY27.
- Advanced plans for international expansion, particularly in the United States, with foundational work completed for market entry.
- Maintained a clear strategic focus on profitable growth, disciplined capital-efficient expansion, and improved cash conversion.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.